Business Description
Evaxion Biotech AS
ISIN : US29970R2040
Share Class Description:
EVAX: ADRDescription
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.51 | |||||
| Equity-to-Asset | -0.37 | |||||
| Debt-to-Equity | -2.29 | |||||
| Debt-to-EBITDA | -0.49 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -16.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 8.3 | |||||
| 3-Year EPS without NRI Growth Rate | 4.4 | |||||
| 3-Year FCF Growth Rate | 6.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 75.51 | |||||
| 9-Day RSI | 70.94 | |||||
| 14-Day RSI | 63.67 | |||||
| 6-1 Month Momentum % | -61.97 | |||||
| 12-1 Month Momentum % | -78.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.18 | |||||
| Quick Ratio | 1.18 | |||||
| Cash Ratio | 0.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -32.8 | |||||
| Shareholder Yield % | -2.73 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -30406.85 | |||||
| Net Margin % | -30308.22 | |||||
| FCF Margin % | -24353.42 | |||||
| ROA % | -131.54 | |||||
| ROIC % | -256.77 | |||||
| ROC (Joel Greenblatt) % | -485.66 | |||||
| ROCE % | -159.08 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 171.1 | |||||
| EV-to-EBIT | -1.25 | |||||
| EV-to-EBITDA | -1.25 | |||||
| EV-to-Revenue | 377.48 | |||||
| EV-to-Forward-Revenue | 1.93 | |||||
| EV-to-FCF | -1.52 | |||||
| Earnings Yield (Greenblatt) % | -80 | |||||
| FCF Yield % | -79.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EVAX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evaxion Biotech AS Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.073 | ||
| EPS (TTM) ($) | -8.1 | ||
| Beta | 0.02 | ||
| Volatility % | 76.87 | ||
| 14-Day RSI | 63.67 | ||
| 14-Day ATR ($) | 0.312293 | ||
| 20-Day SMA ($) | 3.6615 | ||
| 12-1 Month Momentum % | -78.83 | ||
| 52-Week Range ($) | 2.8243 - 18.5 | ||
| Shares Outstanding (Mil) | 5.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evaxion Biotech AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evaxion Biotech AS Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Evaxion Biotech AS Frequently Asked Questions
What is Evaxion Biotech AS(EVAX)'s stock price today?
The current price of EVAX is $4.31. The 52 week high of EVAX is $18.50 and 52 week low is $2.82.
When is next earnings date of Evaxion Biotech AS(EVAX)?
The next earnings date of Evaxion Biotech AS(EVAX) is 2024-05-31 Est..
Does Evaxion Biotech AS(EVAX) pay dividends? If so, how much?
Evaxion Biotech AS(EVAX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers